Study identifier:D5135C00001
ClinicalTrials.gov identifier:NCT01732822
EudraCT identifier:2011-004616-36
CTIS identifier:N/A
A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Peripheral Artery Disease
Phase 3
No
Ticagrelor, Clopidogrel
All
13885
Interventional
50 Years - 130 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Sept 2017 by AstraZeneca
AstraZeneca
-
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Location
Location
CABA, Argentina, C1119ACN
Location
Ciudadela, Argentina, 1702
Location
La Plata, Argentina, B1902COS
Location
La Plata, Argentina, 1900
Location
San Nicolás, Argentina, B2900DMH
Location
Cordoba, Argentina, 5000
Location
Cordoba, Argentina, X5008HHW
Location
Rosario, Argentina, 2000
Arms | Assigned Interventions |
---|---|
Experimental: Ticagrelor Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets | Drug: Ticagrelor Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets Other Name: Brilinta/Brilique |
Active Comparator: Clopidogrel Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets | Drug: Clopidogrel Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets Other Name: Plavix |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.